24 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28650658	54	Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization.	Shandong University
28002667	51	Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe.	Glaxosmithkline
27682507	167	Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300.	Genentech
26701186	50	KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases.	University of Freiburg
26230603	176	Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors.	Glaxosmithkline
25249180	146	The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.	Glaxosmithkline
32453591	70	Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.	University of Illinois At Chicago
32321240	179	Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode.	University of Strathclyde
30998845	58	Discovery of Pyrrolo[3,2- d]pyrimidin-4-one Derivatives as a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor Bromodomain.	Sichuan University
30606676	83	Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.	Gilead Sciences
31910017	43	Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.	Chinese Academy of Sciences
30145373	22	Identification of novel inhibitors of histone acetyltransferase hMOF through high throughput screening.	Chinese Academy of Sciences
30297119	24	Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.	Chinese Academy of Sciences
29657099	55	Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.	Celgene Quanticel Research
29656650	151	Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.	University of Strathclyde
29169673	115	Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300.	Wuxi Apptec
28463487	185	Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.	University of Michigan
29665527	14	Discovery of 1,8-acridinedione derivatives as novel GCN5 inhibitors via high throughput screening.	Shanghai University
30015487	96	Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.	TBA
28892380	93	GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP).	Genentech
28268136	130	Methylpyrrole inhibitors of BET bromodomains.	Abbvie
28949521	88	Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.	Abbvie